Skip to search formSkip to main contentSkip to account menu

BMS 754807

Known as: BMS-754807, BMS754807, Dual IGF-1R/InsR Inhibitor BMS-754807 
An oral small molecule inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases with potential… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (2)

PyrazolesTriazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
IRS 2 Copy Number Gain , KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1 R / IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Insulin-like growth factor receptor 1 (IGF-1R)–targeting therapies are currently at an important crossroad given the low clinical… 
2015
2015
Copy Number Gain , KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1 R / IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Insulin-like growth factor receptor 1 (IGF-1R)–targeting therapies are currently at an important crossroad given the low clinical… 
2013
2013
Abstract 3998: The IGF1 receptor/insulin receptor dual kinase inhibitor BMS-754807 targets the cancer stem cell population in addition to its synergism with Lapatinib in colorectal cancer.
Colon cancer is the second leading cause of cancer mortalities each year. Current treatment options include drugs that target the… 
2013
2013
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by ( 18 F)fluorothymidine-
Summary BMS-754807 is an inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor that also represses… 
2013
2013
Abstract 2945: Anti-tumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Back ground: Insulin-like growth factor-1 receptor… 
Review
2012
Review
2012
Merck Serono spinouts
907 been carried out,” writes Renato Baserga, from the department of Cancer Biology, Thomas Jefferson University in Philadelphia… 
Review
2012
Review
2012
Institutes experiment with a variety of different appeal processes
If at first you don’t succeed, try, try again. That motto has spurred many researchers to challenge the rejection of their grant…